TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06017180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial release technique
Description: It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
Study: NCT04837573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sister Circle protocol
Description: The intervention is an 8-week, therapeutically-informed protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sister Circle protocol
Description: The intervention is an 8-week, therapeutically-informed protocol.
Study: NCT05276258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoSPHERE Ablation
Description: The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
Study: NCT05729932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled vaporized cannabis
Description: Double-blind cannabis and placebo doses, administered through vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled vaporized cannabis
Description: Double-blind cannabis and placebo doses, administered through vaporizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intransal opioid
Description: Double-blind opioid and placebo doses, administered intranasal route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intransal opioid
Description: Double-blind opioid and placebo doses, administered intranasal route
Study: NCT02050009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study: NCT06486571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography recording with HD-sEMG
Description: Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
Study: NCT05878613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill training with KT group (TTKT group)
Description: The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill training without KT group (TT group)
Description: General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
Study: NCT04844554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS 3mA
Description: This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham HD-tDCS
Description: This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
Study: NCT04631432

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-screening
Description: Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.

Intervention type: BEHAVIORAL
Intervention: Task session
Description: The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)
Study: NCT04595617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibodies screening
Description: All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
Study: NCT05624515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Active trigger point puncture of the angularis scapulae muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic compression
Description: Ischaemic compression at the active trigger point of the angularis scapulae muscle
Study: NCT06132711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRIL-BAFF-Bicephali CAR-T cells
Description: Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
Study: NCT05252169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Physical therapy
Description: Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes.
Study: NCT05936788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique
Description: Group A will receive ACBTs with 1 session a day for total 2 days in a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing
Description: Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
Study: NCT04985825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imgatuzumab
Description: Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
Study: NCT06289010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Childhood-Depression (FFT-CD)
Description: This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors.
Study: NCT05665816

Intervention type: DEVICE
Intervention: Stent PULSAR® -18 T3,
Description: Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions.
Study: NCT05477927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual-targeting VEGFR1 and PD-L1 CAR-T cells
Description: In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition.
Study: NCT05199714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Description: Aspart insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Description: Aspart insulin delivered in a basal-bolus manner.
Study: NCT06165575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle
Description: Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham press needle
Description: Sham press needle is a surgical adhesive patch placed on acupuncture points
Study: NCT05744635

Intervention type: DRUG
Intervention: Tacrolimus
Description: Tacrolimus received as part of routine clinical care
Study: NCT06226727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: One tablet administered alone
Study: NCT02050009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05586984

Intervention type: PROCEDURE
Intervention: Laparoscopic uterine lateral suspension
Description: Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.

Intervention type: PROCEDURE
Intervention: Transvaginal sacrospinous fixation
Description: Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
Study: NCT05163249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study: NCT05732103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-712
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-712
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-712
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Study: NCT06017362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Topical insulin 1UI/ml 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: Artificial tears 4 times a day
Study: NCT04937543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled beclametasone
Description: Adding belcamethasone to standard of care for Covid 19 positive patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inahaled beclomethasone / formoterol / glycopyrronium
Description: Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
Study: NCT00781482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone, zolpidem, placebo
Description: In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
Study: NCT04766346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified Cow's Milk-Based Oral Nutritional Supplement
Description: The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
Study: NCT05289037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Study: NCT06089915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard occupational therapy
Description: Standard occupational therapy as part of inpatient rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard occupational therapy
Description: Standard occupational therapy as part of inpatient rehabilitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton
Description: Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
Study: NCT05986279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehab
Description: 6 weeks of vestibular rehabilitation guided by the MINDGAPS decision support system
Study: NCT05441410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine Tetraphosphate, Artesunate Drug Combination
Description: Combination drug for treatment of uncomplicated malaria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (NF54)
Description: cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
Study: NCT06139744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAO supplement
Description: One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
Study: NCT05441410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP
Description: virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride (NaCl) 0.9%
Description: 0.9% NaCl solution for injection